Intellectual property activity in incretin therapeutics accelerated this week as Novo Nordisk disclosed new GLP‑1 receptor agonist polypeptide analogues and Chinese research groups and companies published patent filings for GLP‑1R agonists. The filings span claims on modified peptides and delivery-relevant sequences intended for obesity and diabetes treatment. The wave of patents reflects continued R&D investment following commercial success for GLP‑1 drugs and a push to secure next‑generation sequences and formulations. Expect heightened freedom‑to‑operate negotiations and licensing activity as companies seek to protect or access optimized incretin scaffolds.